1204390-13-5
1204390-13-5
Chemical Structure
Dusigitumab
Synonym(s): MEDI-573
- CAS No.: 1204390-13-5
- Formula:N/A
- Molecular Weight:(144.24 kDa)
IUPAC Name: (3R,4S)-4-(4-fluorophenyl)pyrrolidine-3-carboxylic acid
SMILES: [Dusigitumab]
Biological Activity: Dusigitumab is a fully human IgG2λ monoclonal antibody that targets IGF-1 and IGF-2 with picomolar binding affinity. Dusigitumab blocks IGF-1 and IGF-2-induced phosphorylation of IGF-1R as well as activation of IR-A, thereby inhibiting the activation of downstream signaling pathways. Dusigitumab is applicable to research related to advanced solid tumors and hormone receptor-positive metastatic breast cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Dusigitumab | 96.37% | Dusigitumab is a fully human IgG2λ monoclonal antibody that targets IGF-1 and IGF-2 with picomolar binding affinity. Dusigitumab blocks IGF-1 and IGF-2-induced phosphorylation of IGF-1R as well as activation of IR-A, thereby inhibiting the activation of downstream signaling pathways. Dusigitumab is applicable to research related to advanced solid tumors and hormone receptor-positive metastatic breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. de Bono J, et al. Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. Br J Cancer. 2020;122(9):1324-1332. [Content Brief]
- [2]. Osher E, et al. Therapeutic Targeting of the IGF Axis. Cells. 2019;8(8):895. Published 2019 Aug 14. [Content Brief]
